Cantor Fitzgerald Reiterates Overweight on Bicycle Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintained a $65 price target.
September 12, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Bicycle Therapeutics and maintained a $65 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Bicycle Therapeutics. The maintained price target of $65 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100